PSIL
·NYSE
--
--(--)
--
--(--)
Key Stats
Assets Under Management
18.86MUSD
Fund Flows (1Y)
7.18MUSD
Dividend Yield
1.34%
Discount/Premium to NAV
-0.83%
Shares Outstanding
1.00M
Expense Ratio
1.00%
About AdvisorShares Psychedelics ETF
Issuer
AdvisorShares
Brand
AdvisorShares
Home Page
Inception Date
Sep 15, 2021
Structure
Open-Ended Fund
Index Tracked
--
Management Style
Active
Dividend Treatment
Distributes
Distribution Tax Treatment
Qualified dividends
Income Tax Type
Capital Gains
Max ST Capital Gains Rate
39.60%
Max LT Capital Gains Rate
20.00%
Primary Advisor
AdvisorShares Investments LLC
Distributor
Foreside Fund Services LLC
PSIL is an actively-managed portfolio of publicly-listed companies that derive at least 50% of their revenue or devote 50% of their assets to legal activities related to psychedelic medicines and their derivatives, excluding cannabis. It invests in stocks of US and foreign mid-, small-, and micro-cap firms and in swaps that provide the same exposure. PSIL aims to concentrate at least 25% of its investments in the Pharmaceuticals, Biotechnology & Life Sciences industry group. The fund adviser uses outside analyst ratings and stock selection rating tools to select companies that dominate their respective industries or are in unique positions for growth and expansion. Additionally, the fund has the ability to engage in stock lending, up to 33.3% of the portfolio, in order to increase income to the issuer.
Classification
Asset Class
Equity
Category
Sector
Focus
Health Care
Niche
Pharma, Biotech & Life Sciences
Strategy
Active
Geography
Global
Weighting Scheme
Proprietary
Selection Criteria
Proprietary
Returns
1-Month | 3-Month | YTD | 1-Year | 3-Year | 5-Year | |
|---|---|---|---|---|---|---|
Price Performance | +1.36% | +5.62% | +68.42% | +75.40% | -10.96% | -81.59% |
NAV Total Return | +3.08% | +10.53% | +62.98% | +83.59% | -8.81% | -0.86% |
Ratings
No data is currently available
Ainvest’s AI-powered ETF Scoring Algorithm, built to help retail investors make smarter, data-driven decisions. Leveraging deep learning, reinforcement learning, and large language models, the algorithm scores ETFs across five key dimensions: Fund Flow, Momentum, Safety, Fundamentals, and Performance. Each factor is weighted by its correlation to future returns, resulting in a single, actionable score. Backtested over five years with consistently strong predictive accuracy. Ainvest brings institutional-grade artificial intelligence to everyday investors—transforming complexity into clarity with every score.
Holdings Analysis
Sector
Healthcare
100.00%
Healthcare
100.00%
Asset
Region
73.64%
25.03%
1.33%
Category
Ratio
North America
73.64%
Europe
25.03%
Australasia
1.33%
Investment Style
No data is currently available
Top 10 Holdings
Symbol
Ratio
ATAI
Atai Beckley
11.01%
CMPS
COMPASS Pathways
7.81%
SUPN
Supernus
7.72%
RLMD
Relmada Therapeutics
7.26%
MNMD
Mind Medicine
7.14%
ANRO
Alto Neuroscience
6.06%
DRUG
Bright Minds
5.62%
NBIX
Neurocrine Biosciences
5.56%
NRXP
NRX Pharmaceuticals
4.85%
CYBN
Cybin
4.85%
Top 10 Weight 67.88%
29 Total Holdings
Dividends
Dividend Payout History
Declaration Date | Record Date | Payment Date | Amount |
|---|---|---|---|
| 2025-09-22 | 2025-09-22 | 2025-09-29 | 0.020 |
| 2025-06-23 | 2025-06-23 | 2025-06-27 | 0.012 |
| 2025-03-21 | 2025-03-21 | 2025-03-28 | 0.163 |
| 2024-12-23 | 2024-12-23 | 2024-12-30 | 0.055 |
| 2023-09-25 | 2023-09-26 | 2023-09-29 | 0.003 |
| 2022-09-26 | 2022-09-27 | 2022-09-30 | 0.054 |
Premium/Discount Chart
Premium/Discount to NAV
Price
1M
Assets Under Management
Assets Under Management
1M
Fund Flows
Inflows
Outflows
1M
